|1.||Forrat, R: 1 article (11/2000)|
|2.||Kamga-Fotso, L: 1 article (11/2000)|
|3.||Peyrieux, J C: 1 article (11/2000)|
|4.||Lang, J: 1 article (11/2000)|
|5.||Lutsch, C: 1 article (11/2000)|
|6.||Blondeau, C: 1 article (11/2000)|
11/01/2000 - "Repeated measures of equine tetanus-antibody levels measured from Day 0 to Day 28 showed that titers were significantly higher in the HT-ETIG group (P = 0.017). "
11/01/2000 - "A total of 134 adults presenting to Garoua Hospital, Cameroon with a tetanus-prone wound were randomized to receive a 3,000 international units (IU) intramuscular injection (deltoid) of either HT-ETIG or ETIG, simultaneously with a tetanus-diphtheria vaccine. "
11/01/2000 - "In a single-center double-blind, randomized trial in West Africa, we evaluated the safety and immunogenicity of a new pasteurized, pepsin-digested equine tetanus immunoglobulin (heat-treated equine tetanus immunoglobulin [HT-ETIG]) in the post-exposure prophylaxis of tetanus compared with the reference product, equine tetanus immunoglobulin (ETIG). "
|2.||Wounds and Injuries (Trauma)
|1.||heat-treated equine tetanus immunoglobulin
|2.||Pepsin A (Pepsin)
|4.||Diphtheria Toxoid (Vaccine, Diphtheria)